drugset / Trial / NCT01069510
Spironolactone in Adult Congenital Heart Disease
Phase 2
Completed
40 enrolled
Oregon Health and Science University
National Heart, Lung, and Blood Institute (NHLBI) · collabOregon Clinical and Translational Research Institute · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to see if the study drug called spironolactone reduces fibrous (stiffening) in heart muscle tissue and improves heart function. Subjects from the study titled "Heart Failure in Congenital Heart Disease: the role of myocardial fibrosis" who have evidence of heart dysfunction and/or evidence of fibrosis (stiffening) in the heart muscle will be asked to take part in this study.
Timeline
- Start
- 2010-02
- Primary completion
- 2016-06
- Completion
- 2017-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Spironolactone | Small molecule | 25 mg | — |